Clinical Trials Browser

Phase 2 × NIH × sacituzumab govitecan × Clear all

NCT06161532 2026-03-17

Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...

Phase 2 Recruiting

Carcinoma, Transitional Cell

NCT06311214 2026-03-06

Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)

Phase 2 Recruiting

Neoplasm Metastasis

NCT06865677 2026-01-21

Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas

Phase 2 Terminated

2 enrolled 7 charts

Recurrence